Non-Insulin Therapies for Diabetes Market Size - By Type(Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, GLP-1 Analogs, Sodium-glucose co-transporter-2 (SGLT2) inhibitors), by Route of Administration(Oral, Intramuscular), by Distribution Channel(Retail Pharmacy, Hospital Pharmacy, Online Pharmacy) & Region - Forecasts 2023 -2033
- PUBLISHED ON
- 2024-08-04
- NO OF PAGES
- 225
- CATEGORY
- Healthcare & Life Sciences
Non-Insulin Therapies for Diabetes Market: Description
Non-insulin therapies are normally used in type 2 diabetes patients, where body either doesn't convey sufficient insulin or can't effectively use the insulin it produces. Non-insulin-based drug works with different arrangement of activities to reduce blood glucose level and maintain ideal glycaemic control. For instance, a couple of administrators increase the insulin release from pancreatic cells (Sulfonylureas), whereas certain experts increase glucose take-up by periphery and diminishes hepatic glucose yield (Biguanides), On the other hand, many administrators prevent absorption of starch in small gastrointestinal system (alpha glucosidase inhibitors), and some solutions diminish post supper sugar by hindering specific chemical.
Source: WMR
Non-Insulin Therapies for Diabetes Market: Overview
The Non-Insulin Therapies for Diabetes Market size was $ 61.090.1 million in 2022, and is anticipated to increase to a worth of more than $ 105,461.5 million by 2033, registering a CAGR (compound annual growth rate) of over 6% from 2023 to 2033.
The main considerations driving the development of the market is the rapid expansion in the quantity of individuals impacted by Diabetes Type 2. The engagement of organizations to produce drugs with less incidental effects has contributed a ton to the development of the market. Non-insulin drugs, when infused into the body, assists the liver to produce insulin. Although, the insulin market ruled previously, but these kind of the non-insulin drug will soon be at a similar level as insulin type drugs. The change is way of life and food habits are the reason for diabetes, and along these lines, they will push forward market progression.
The key challenge for this market is to produce drugs that have less aftereffects and more efficient than the currently utilized drugs. The advantages of these medications are still unknown to many, so less awareness is likewise a challenge. The accessibility of these medications to all sections of the population is additionally a major challenge as diabetes is a typical disease. The overall awareness about the functions and employments of these medications is not known to many, so increasing the cognizance level of the individuals is another challenge for this market. The public authority drives about spreading awareness among these masses on the function and availability of these drugs are not on a large scale and in this way limit the development of the market.
Source: WMR
Non-Insulin Therapies for Diabetes Market: Key trends
· Developing Prevalence of Non-Invasive Treatments to Dive the Growth
Growing overall rate and preponderance of diabetes is depended upon to fuel advancement of the non-insulin treatment for diabetes promote. Non-insulin treatment is prevalently used in type 2 diabetes, which addresses a huge share of the overall diabetes cases. As demonstrated by the International Diabetes Federation's (IDF) Diabetes Atlas 2017, generally frequency of diabetic patients was more than 400 million, of which larger part were encountering type 2 diabetes. As per the World Health Organization (WHO) 2017 report, diabetes is one of the super three reasons behind death among non-infectious diseases globally. This is the main consideration that supports the expansion of worldwide non-insulin therapies for diabetes market.
· New Product Launches to Boost the Growth
Healthcare companies and related organizations are launching and approving new products and treatments in the market, which is depended upon to drive increment of the overall non-insulin treatment for diabetes market. For instance, in 2017, the Food and Drug Administration (FDA) avowed Novo Nordisk's Ozempic, which is before seven days GLP-1 simple, would assemble the patient consistence. In December 2017, FDA insisted ertugliflozin made by the Merck and Co. additionally, Pfizer Inc. similarly, in January 2018, the European Medicines Agency (EMA) permitted support for the equivalent in Europe.
Non-Insulin Therapies for Diabetes Market: Segment Analysis
Non-Insulin Therapies for Diabetes Market based on Drug type
· Sulphonylureas
· Biguanides
· Thiazolidinediones
· Alpha-Glucosidase Inhibitors
· Dipeptidyl Peptidase-4 (DPP4) Inhibitors
· Type_ GLP-1 Analogs
· Sodium-glucose co-transporter-2 (SGLT2) inhibitors
The Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor's segment is likely to observe vigorous development during the esteemed time frame in view of the drug type. The main reason adding to this segmental growth can be credited to the high efficacy of thus drug as it can be used both as monotherapy or combination treatment.
Non-Insulin Therapies for Diabetes Market based on route of administration
· Oral
· Intramuscular
Source: WMR
Non-Insulin Therapies for Diabetes Market based on distribution channel
· Retail Pharmacy
· Hospital Pharmacy
· Online Pharmacy
Non-Insulin Therapies for Diabetes Market - Geographical ambit
In term of geographic region, the non-insulin therapies for diabetes market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America had the biggest share in 2020 and is relied upon to develop with a healthy rate during the projected timeline. The rising prevalence of diabetes is the essential component supporting the development rate. The other factors impelling the market are numerous ongoing clinical preliminaries and the accessibility of further develop treatment choices and healthcare infrastructure. The presence of worldwide players will influence the market emphatically.
Non-Insulin Therapies for Diabetes Market: Competitive Landscape
The major players operating in the marketplace are AstraZeneca, Boehiringer Ingelheim GmbH, Bristol-Myers Squibb, Eli, Lilly and Company, GlaxoSmithKline, F.Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis, GSK, Intarcia Therapeutics, Jiangsu Hansoh Pharmaceutical, Emisphere, Uni-Bio Science Group, Takeda Pharmaceuticals, and Others.
To endure the cutthroat and divided nature of the global non-insulin therapies for diabetes market, players are taking on methodologies like partnership, joint efforts, and consolidations. These techniques permit the players to extend their business at a worldwide level. Furthermore, with these methodologies, the associations can reach to the undiscovered regions that can be worthwhile for the business. These methodologies likewise permit the organizations to secure assets that can additionally add to their manageability and achievement in the worldwide non-insulin therapies for diabetes market.
On the other side, recognized players are fusing trend setting innovations in their items. These innovations can foresee, monitor, and adjust according the utilization. These mechanical improvements give the producers a strategic advantage over their opponents that further assist them with having a fortification over the global non-insulin therapies for diabetes market.
Report Scope:
Non-Insulin Therapies for Diabetes Market Forecast Years: 2023-2033
Non-Insulin Therapies for Diabetes Market Historical Years: 2020-2021
Non-Insulin Therapies for Diabetes Market 2022: $61.090.1 million
Non-Insulin Therapies for Diabetes Market 2033: $105,461.5 million
Non-Insulin Therapies for Diabetes Market CAGR: 6%
Key Segments: Drug type, and geographic region.
Key Regions & Countries: North America (the United States, Canada, and Mexico), Europe, (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, Colombia, etc.), and The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa).
Key Players: AstraZeneca, Boehiringer Ingelheim GmbH, Bristol-Myers Squibb, Eli, Lilly and Company, GlaxoSmithKline, F.Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis, GSK, Intarcia Therapeutics, Jiangsu Hansoh Pharmaceutical, Emisphere, Uni-Bio Science Group, Takeda Pharmaceuticals, and Others.
1. Global Non-Insulin Therapies for Diabetes Market Introduction and Market Overview
1.1. Objective of the Market Research Study
1.2. Non-Insulin Therapies for Diabetes Market Definition & Description
1.3. Research Data Parameters & Reporting Timelines
1.3.1. Historical Data Reporting Years – 2020 to 2021
1.3.2. Projected Data Reporting Years – 2022 to 2033
1.3.3. Reporting Data Parameters – Value (US$ Million)
1.4. Global Non-Insulin Therapies for Diabetes Market Scope and Market Estimation
1.4.1. Global Non-Insulin Therapies for Diabetes Overall Market Size (US$ Million), Market CAGR (%), Market Estimates & Forecast (2020 to 2033)
1.4.2. Global Non-Insulin Therapies for Diabetes Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2020 to 2033
1.5. Non-Insulin Therapies for Diabetes Market Segmentation
1.5.1. Type of Global Non-Insulin Therapies for Diabetes Market
1.5.2. Route of Administration of Global Non-Insulin Therapies for Diabetes Market
1.5.3. Distribution Channel of Global Non-Insulin Therapies for Diabetes Market
1.5.4. Key Regions of Global Non-Insulin Therapies for Diabetes Market
2. Global Non-Insulin Therapies for Diabetes Market - Executive Summary
2.1. Global Non-Insulin Therapies for Diabetes Market – Summary & Snapshot
2.2. Global Non-Insulin Therapies for Diabetes Market, By Type (US$ Million)
2.3. Global Non-Insulin Therapies for Diabetes Market, By Route of Administration (US$ Million)
2.4. Global Non-Insulin Therapies for Diabetes Market, By Distribution Channel (US$ Million)
2.5. Global Non-Insulin Therapies for Diabetes Market, By Geography (US$ Million)
2.6. Global Non-Insulin Therapies for Diabetes Market Outlook & Future Opportunities
3. Non-Insulin Therapies for Diabetes Market Trends, Outlook, and Factors Analysis
3.1. Global Non-Insulin Therapies for Diabetes Market Industry Development Trends under COVID-19 Outbreak
3.1.1. Global COVID-19 Status Overview
3.1.2. Influence of COVID-19 Outbreak on Global Non-Insulin Therapies for Diabetes Market Industry Development
3.1.3. Pre & Post COVID-19 Trends and Scenarios
3.2. Non-Insulin Therapies for Diabetes Market Dynamics (Growth Impacting Factors & Rationales)
3.2.1. Drivers
3.2.1.1. Non-insulin-based medication helps in different mechanism such as reduce blood glucose level and maintain it for optimum glycemic control, these usage has been driving the market.
3.2.1.2. Driver 2
3.2.1.3. Driver 3
3.2.2. Restraints
3.2.2.1. Non-insulin based drugs of some class are high enough for everyone to afford it.
3.2.2.2. Restraint 2
3.2.3. Opportunities
3.2.3.1. New class of Non-insulin based drugs are being developed by various market players to with stand the market and have their share.
3.2.3.2. Opportunity 2
3.2.3.3. Opportunity 3
3.2.4. Impact Analysis of Drivers and Restraints
3.3. Ecosystem/ Value Chain Analysis
3.4. Porter’s Five Forces Analysis
3.5. SWOT Analysis
3.6. PEST Analysis
3.7. Average Selling Prices and Pricing Trends Analysis of Non-Insulin Therapies for Diabetes Market
3.8. Technological Roadmap
3.9. Key Investment Pockets of Non-Insulin Therapies for Diabetes Market
3.9.1. By Type
3.9.2. By Route of Administration
3.9.3. By Distribution Channel
3.9.4. By Regions
4. Global Non-Insulin Therapies for Diabetes Market: Estimates & Historic Trend Analysis (2020 to 2021)
4.1. Global Non-Insulin Therapies for Diabetes Market, 2020 – 2021 (US$ Million)
4.2. Global Non-Insulin Therapies for Diabetes Market, By Type, 2020 to 2021 (US$ Million)
4.3. Global Non-Insulin Therapies for Diabetes Market, By Route of Administration, 2020 to 2021 (US$ Million)
4.4. Global Non-Insulin Therapies for Diabetes Market, By Distribution Channel, 2020 to 2021 (US$ Million)
4.5. Global Non-Insulin Therapies for Diabetes Market, By Region, 2020 to 2021 (US$ Million)
5. Global Non-Insulin Therapies for Diabetes Market Estimates & Forecast Trend Analysis, by Type
5.1. Global Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, by Type, 2022 & 2033
5.2. Global Non-Insulin Therapies for Diabetes Market Revenue (US$ Million) Estimates and Forecasts, by Type, 2022 to 2033
5.2.1. Type_ Biguanides
5.2.2. Type_ Sulfonylureas
5.2.3. Type_ Thiazolidinedione’s
5.2.4. Type_ Alpha-Glucosidase Inhibitor
5.2.5. Type_ DPP-4 Inhibitors
5.2.6. Type_ GLP-1 Analogs
5.2.7. Type_ Sodium-glucose co-transporter-2 (SGLT2) inhibitors
6. Global Non-Insulin Therapies for Diabetes Market Estimates & Forecast Trend Analysis, by Route of Administration
6.1. Global Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, by Route of Administration, 2022 & 2033
6.2. Global Non-Insulin Therapies for Diabetes Market Revenue (US$ Million) Estimates and Forecasts, by Route of Administration, 2022 to 2033
6.2.1. Route of Administration_ Oral
6.2.2. Route of Administration_ Intramuscular
7. Global Non-Insulin Therapies for Diabetes Market Estimates & Forecast Trend Analysis, by Distribution Channel
7.1. Global Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, by Distribution Channel, 2022 & 2033
7.2. Global Non-Insulin Therapies for Diabetes Market Revenue (US$ Million) Estimates and Forecasts, by Distribution Channel, 2022 to 2033
7.2.1. Distribution Channel_ Retail Pharmacy
7.2.2. Distribution Channel_ Hospital Pharmacy
7.2.3. Distribution Channel_ Online Pharmacy
8. Global Non-Insulin Therapies for Diabetes Market Analysis and Forecast, by Region
8.1. Global Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, by Region, 2022 & 2033
8.2. Global Non-Insulin Therapies for Diabetes Market Revenue (US$ Million) Estimates and Forecasts, by Region, 2022 to 2033
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Middle East and Africa
8.2.5. Latin America
9. North America Non-Insulin Therapies for Diabetes Market: Estimates & Forecast Trend Analysis
9.1. North America Non-Insulin Therapies for Diabetes Market Assessments & Key Findings
9.2. North America Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, 2022 & 2033
9.3. North America Non-Insulin Therapies for Diabetes Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
9.3.1. By Type
9.3.2. By Route of Administration
9.3.3. By Distribution Channel
9.3.4. By Major Country
9.3.4.1. The U.S.
9.3.4.2. Canada
10. Europe Non-Insulin Therapies for Diabetes Market: Estimates & Forecast Trend Analysis
10.1. Europe Non-Insulin Therapies for Diabetes Market Assessments & Key Findings
10.2. Europe Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, 2022 & 2033
10.3. Europe Non-Insulin Therapies for Diabetes Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
10.3.1. By Type
10.3.2. By Route of Administration
10.3.3. By Distribution Channel
10.3.4. By Major Country
10.3.4.1. Germany
10.3.4.2. The U.K.
10.3.4.3. France
10.3.4.4. Italy
10.3.4.5. Spain
10.3.4.6. Rest of Europe (includes all other European countries)
11. Asia Pacific Non-Insulin Therapies for Diabetes Market: Estimates & Forecast Trend Analysis
11.1. Asia Pacific Non-Insulin Therapies for Diabetes Market Assessments & Key Findings
11.2. Asia Pacific Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, 2022 & 2033
11.3. Asia Pacific Non-Insulin Therapies for Diabetes Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
11.3.1. By Type
11.3.2. By Route of Administration
11.3.3. By Distribution Channel
11.3.4. By Major Country
11.3.4.1. China
11.3.4.2. Japan
11.3.4.3. India
11.3.4.4. ASEAN
11.3.4.5. South Korea
11.3.4.6. Rest of Asia Pacific (includes all other Asia Pacific countries)
12. Middle East & Africa Non-Insulin Therapies for Diabetes Market: Estimates & Forecast Trend Analysis
12.1. Middle East & Africa Non-Insulin Therapies for Diabetes Market Assessments & Key Findings
12.2. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, 2022 & 2033
12.3. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
12.3.1. By Type
12.3.2. By Route of Administration
12.3.3. By Distribution Channel
12.3.4. By Major Country
12.3.4.1. GCC
12.3.4.2. South Africa
12.3.4.3. Egypt
12.3.4.4. Rest of Middle East & Africa (includes all other Middle East & Africa countries)
13. Latin America Non-Insulin Therapies for Diabetes Market: Estimates & Forecast Trend Analysis
13.1. Latin America Market Assessments & Key Findings
13.2. Latin America Non-Insulin Therapies for Diabetes Market Share (%) Estimates and Forecasts, 2022 & 2033
13.3. Latin America Non-Insulin Therapies for Diabetes Market Size Estimates and Forecast (US$ Million) (2022 to 2033)
13.3.1. By Type
13.3.2. By Route of Administration
13.3.3. By Distribution Channel
13.3.4. By Major Country
13.3.4.1. Brazil
13.3.4.2. Mexico
13.3.4.3. Rest of Latin America (includes all other Latin America countries)
14. Competitive Landscape
14.1. Non-Insulin Therapies for Diabetes Market Revenue Share Analysis (%), by Major Players (2021)
14.2. Non-Insulin Therapies for Diabetes Market Competition Matrix, by Leading Players
14.3. Non-Insulin Therapies for Diabetes List of Emerging, Prominent and Leading Players
14.4. Major Mergers & Acquisitions, Partnership, Joint Venture, Expansions, Deals, Recent Developments, etc.
15. Company Profiles
15.1. AstraZeneca
15.1.1. Company Overview & Insights
15.1.2. Financial Performance
15.1.3. Product / Service Portfolio
15.1.4. Geographical Footprint & Share
15.1.5. Strategic Initiatives & Key Developments
*Similar details would be provided for all the players mentioned below
15.2. Boehringer Ingelheim GmbH,
15.3. Bristol-Myers Squibb,
15.4. Eli Lilly and Company,
15.5. GlaxoSmithKline,
15.6. F. Hoffmann-La Roche Ltd.,
15.7. Janssen Pharmaceuticals,
15.8. Merck and Company,
15.9. Novartis AG,
15.10. Novo Nordisk,
15.11. Pfizer,
15.12. Sanofi Aventis,
15.13. GSK
15.14. INTARCIA THERAPEUTICS
15.15. JIANGSU HANSOH PHARMACEUTICAL
15.16. NOVO NORDISK
15.17. EMISPHERE
15.18. UNI-BIO SCIENCE GROUP
15.19. Takeda Pharmaceuticals
15.20. Others
16. Assumptions and Research Methodology
16.1. Data Mining
16.2. Secondary Research
16.3. Primary Research
16.4. Subject Matter Expert Advice
16.5. Quality Check
16.6. Final Review
16.7. Data Triangulation
16.8. Bottom-Up Approach
16.9. Top Down Approach
16.10. Research Flow
16.11. Key Insights from Industry Experts
16.12. Data Sources
16.13. Assumptions
16.14. Limitations
17. Conclusions and Recommendations
17.1. Key Research Findings and Conclusion
17.2. Key Insights & Recommendations from Analysts
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
}})
Select a license type that suits your business needs
US $3499
Only Three Thousand Four Hundred Ninety Nine US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $4499
Only Four Thousand Four Hundred Ninety Nine US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $5499
Only Five Thousand Four Hundred Ninety Nine US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI